72
74
Growth Score
-1 pts
Heat Score
34 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
78428
SERB Pharmaceuticals focuses on treating critical conditions, primarily in emergency care and rare diseases.
- Vanessa Wolfeler: Chief Executive OfficerPast Role: Sanofi, Head of US Respiratory & Gastroenterology
- Vignesh Rajah: Chief Medical OfficerPast Role: Y-mAbs Therapeutics, SVP, CMO & Head of Late-Stage Development
About the Company
SERB Pharmaceuticals is a specialty pharmaceutical company that focuses on the treatment of patients with critical conditions. The company's primary focus is on emergency care and rare diseases. SERB Pharmaceuticals is a combination of SERB, BTG Specialty Pharmaceuticals, and Veriton Pharma, forming a growing specialty pharmaceutical entity.
The company also aims to build up management systems that match global practices in the promotion and funding of basic research. They have developed a scheme called SERB-SUPRA for scientific and useful profound research, including drug discovery and the study of chemical toxicity.
